Navigation Links
Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
Date:11/25/2009

BASKING RIDGE, N.J., Nov. 25 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David Mazzo, PhD, CEO and President, will be presenting at the Piper Jaffray 21st Annual Health Care Conference at the New York Palace Hotel in New York City. Dr. Mazzo's presentation will be given at 1:10pm (EST) on Tuesday, December 1 and will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. The healthcare industry's leading senior management teams will be presenting at this conference to top institutional investors, equity portfolio managers and research analysts worldwide.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is inten
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
2. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
5. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
6. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
7. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
8. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
9. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Calif. , May 1, 2015 The ... its 2015 health literacy award winners. The IHA Health ... that make an impact on the practice of educating ... health literacy. IHA gives awards in three categories: innovative ... bestowed its Health Literacy Hero award. In ...
(Date:5/1/2015)... Semler Scientific, Inc. (Nasdaq: SMLR ), ... and markets products that assist healthcare providers in monitoring ... for the first quarter ended March 31, 2015. ... reported continued progress with year over year growth of ... 14%," said Doug Murphy-Chutorian , M.D., chief executive ...
(Date:5/1/2015)... -- Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) ... results of the Phase 3 Rocket 1 trail of ... to meet its end points, compelling data from the ... studies. An analyst report on AERI that ... analyst summary, valuation, and recommendation can be viewed by ...
Breaking Medicine Technology:Institute for Healthcare Advancement Announces 2015 Award Winners 2Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... FARMINGDALE, N.Y., Feb. 9, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative, therapeutic, ... neurosurgery, laparoscopic surgery, and other surgical and medical ... fiscal quarter and six months ending December 31, ...
... SAN FRANCISCO, Feb. 9, 2011 SYNARC, ... to the pharmaceutical and biotechnology industries, announced today that ... and marketing efforts in support of the company,s rapidly ... Ciaran Cooper, a pioneer in the clinical trials ...
Cached Medicine Technology:Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 2Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 3Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 4Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 5Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 6SYNARC Appoints Ciaran Cooper as Vice President, Business Development 2
(Date:5/2/2015)... May 03, 2015 As one of ... the prestigious Safety and Health Achievement and Recognition Program ... to be chosen by the Illinois Department of Labor ... achieved and maintained SHARP certification by the Occupational Safety ... as Essentra has continued to meet or exceed all ...
(Date:5/2/2015)... Vancouver fencing company, QS Fencing, has recently announced ... prospective clients related to their questions on railings and gates. ... their decks and patios. While that seems like an easy ... the person rolls up their sleeve to start working. One ... finding a gate that matches it. , Instead of spending ...
(Date:5/2/2015)... Aliso Viejo, CA (PRWEB) May 02, 2015 ... made exclusively for use in Final Cut Pro X. ... ready for use in Final Cut Pro X . ... a single keyframe with Pixel Film Studios' ProText Kinetic 2. ... drop. Start by staggering two ProText Kinetic presets in ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... On Tuesday April 7th, the patient ... to celebrate improvements in patient care. In 2014 the ... had zero acquired ventilator associated infections, zero central line ... was also recently named a Top Performer by the ... credited the teamwork of staff from all departments involved ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... Medicare ... ... -- If you’re one of the more than 45 million people relying on Medicare for ... is too expensive, according to Allsup , a nationwide provider of Social Security disability ...
... , , , ... NXTM ), a leading manufacturer of innovative dialysis products, today ... Chief Financial Officer, will be presenting at the UBS Global Life ... Grand Central in New York City. , , ...
... , , BIRMINGHAM, Ala., ... leader in radiology optimization solutions that increase business capacity, productivity ... its Board of Directors has approved changing its name to ... its ability to more accurately represent the precision imaging management ...
... , , FRANKLIN LAKES, N.J., Sept. 1 BD ... that it would present at the following investor healthcare conferences in September: , , ... September 9, 2009, 10:55 ... September 14, 2009, ...
... rank facilities don,t take all measurements into account , TUESDAY, ... onto the U.S. News & World Report list ... in some measurements regarding heart failure, researchers say. , "If ... the areas of heart failure mortality and readmission, you should ...
... , PISCATAWAY, N.J., Sept. 1 Milestone ... advanced injection technologies, today announced that Leslie Bernhard, an independent ... Osser who had previously led the Company as Chairman since ... Chief Executive Officer since February 2009 and was formerly Milestone,s ...
Cached Medicine News:Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 2Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 3Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 4Health News:Allsup Outlines 10 Critical Questions to Answer When Evaluating Medicare Plans 5Health News:NxStage to Present at the UBS Global Life Sciences Conference 2Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 2Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 3Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 4Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 5Health News:Optimal Readings Completes Strategic Name Change to Optimal IMX 6Health News:Government Best Source for U.S. Hospital Data, Study Finds 2Health News:Milestone Scientific Announces Key Leadership Changes 2Health News:Milestone Scientific Announces Key Leadership Changes 3
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
... collagen hemostat. FirstStop is a non-friable, non-woven ... characteristics. It can easily be cut to ... FirstStop products are not dispersed when wet ... hemostasis is achieved. As the collagen forms ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: